ADVERTISEMENTs
Garuda Therapeutics names Avanish Vellanki as CEO
Vellanki will lead the company in advancing off-the-shelf hematopoietic stem cell therapies, driving innovation and expanding clinical validation efforts.
.jpeg)
Avanish Vellanki / LinkedIn
Massachusetts-based biotechnology company Garuda Therapeutics has appointed Avanish Vellanki as its president, chief executive officer, and director on its board.
Vellanki takes over from interim CEO Adam Craig, who will continue to serve as an independent board member.
Also read: ASAPP elevates Priya Vijayarajendran as CEO
“Avanish has extensive experience in building companies with an enduring focus on patients. His leadership will play a significant role in driving Garuda’s novel hematopoietic stem cell therapy technology,” said Eric Aguiar, chairman of the board.
Vellanki, who co-founded and previously led Rain Oncology, brings over two decades of experience spanning healthcare and investment banking. his career includes roles at Bear, Stearns, Citigroup, Proteolix, and Onyx Pharmaceuticals.
At Proteolix, he contributed to the development of carfilzomib (kyprolis®) for multiple myeloma treatment. He later served as senior vice president and chief business officer at Aptose Biosciences.
“It is a privilege to join Garuda at this pivotal time, and I’m excited to help build the company as it moves closer to clinically validating the potential of its platform,” Vellanki said.
Craig, who served as interim CEO, expressed confidence in Vellanki’s leadership. “I am proud to hand over the reins to Avanish, who possesses the leadership and strategic vision to propel Garuda to new milestones. Iam confident Garuda will continue to innovate and thrive under Avanish’s leadership.”
Garuda Therapeutics is focused on developing off-the-shelf hematopoietic stem cell therapies, aiming to provide immediate and accessible solutions for patients with severe and life-threatening diseases.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
.jpg)
Video
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login